Unexpected Sensitivity of Nonobese Diabetic Mice With a Disrupted Poly(ADP-Ribose) Polymerase-1 Gene to Streptozotocin-Induced and Spontaneous Diabetes
- Cristina Gonzalez1,
- Josiane Ménissier de Murcia2,
- Philip Janiak3,
- Jean-Pierre Bidouard3,
- Catherine Beauvais1,
- Saoussen Karray1,
- Henri-Jean Garchon1 and
- Matthieu Lévi-Strauss1
- 1Institut National de la Santé et de la Recherche Médicale, Unité 25, Hôpital Necker, Paris, France
- 2Centre National de la Recherche Scientifique, Ecole Supérieure de Biotechnologie de Strasbourg, Illkirch, France
- 3Sanofi-Synthélabo Recherche, Département Cardio-Vasculaire, Chilly Mazarin Cedex, France
Abstract
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that consumes NAD in response to DNA strand breaks. Its excessive activation seems particularly deleterious to pancreatic β-cells, as exemplified by the complete resistance of PARP-1-deficient mice to the toxic diabetes induced by streptozotocin. Because of the possible implication of this enzyme in type 1 diabetes, many human trials using nicotinamide, an inhibitor of PARP-1, have been conducted either in patients recently diagnosed or in subjects highly predisposed to this disease. To analyze the role of this enzyme in murine type 1 diabetes, we introgressed a disrupted PARP-1 allele onto the autoimmune diabetes-prone nonobese diabetic (NOD) mouse strain. We showed that these mice were protected neither from spontaneous nor from cyclophosphamide-accelerated diabetes. Surprisingly they were also highly sensitive to the diabetes induced by a single high dose of streptozotocin, standing in sharp contrast with C57BL/6 mice that bear the same inactivated PARP-1 allele. Our results suggest that NOD mice are characterized not only by their immune dysfunction but also by a peculiarity of their islets leading to a PARP-1-independent mechanism of streptozotocin-induced β-cell death.
Footnotes
-
Address correspondence and reprint requests to Matthieu Lévi-Strauss, INSERM, Unité 25, Hôpital Necker, 161 rue de Sèvres, 75743 Paris Cedex 15, France. E-mail: lstrauss{at}infobiogen.fr.
Received for publication 17 December 2001 and accepted in revised form 31 January 2002.
P.J. and J.-P.B. are employees of Sanofi-Synthelabo Research, which manufactures and markets pharmaceuticals related to the treatment of diabetes and its complications.
MEM, minimum essential medium; PARP, poly(ADP-ribose) polymerase; SPF, specific pathogen free.
- DIABETES














